[Immunomodulators in therapy for chronic virus hepatitis C].
The authors present the results of their investigations of clinical and immunological characteristics in chronic viral hepatitis C (CVHC). Cellular and humoral immunological parameters and cytokine profile, including the interferon status, were studied in relation to the activity of the process. Statistically significant clinical laboratory and immunological differences were found in patients (CVHC) receiving various treatment options. The clinical efficacy of immunomodulators of the groups of aminophthalhydrazides (galavit, tamerit) and muramyl peptides (glymuride) in the combination therapy of CVHC was evaluated.